eCite Digital Repository

Astaxanthin vs placebo on arterial stiffness, oxidative stress and inflammation in renal transplant patients (Xanthin): A Randomised Controlled Trial

Citation

Fassett, RG and Healy, H and Driver, R and Robertson, IK and Geraghty, DP and Sharman, JE and Coombes, JS, Astaxanthin vs placebo on arterial stiffness, oxidative stress and inflammation in renal transplant patients (Xanthin): A Randomised Controlled Trial, BMC Nephrology, 18, (9) pp. 17. ISSN 1471-2369 (2008) [Refereed Article]


Preview
PDF
316Kb
  

Copyright Statement

Copyright 2008 BioMed Central Ltd

DOI: doi:10.1186/1471-2369-9-17

Abstract

Background: There is evidence that renal transplant recipients have accelerated atherosclerosis manifest by increased cardiovascular morbidity and mortality. The high incidence of atherosclerosis is, in part, related to increased arterial stiffness, vascular dysfunction, elevated oxidative stress and inflammation associated with immunosuppressive therapy. The dietary supplement astaxanthin has shown promise as an antioxidant and anti-inflammatory therapeutic agent in cardiovascular disease. The aim of this trial is to investigate the effects of astaxanthin supplementation on arterial stiffness, oxidative stress and inflammation in renal transplant patients. Method/Design This is a randomised, placebo controlled clinical trial. A total of 66 renal transplant recipients will be enrolled and allocated to receive either 12 mg/day of astaxanthin or an identical placebo for one-year. Patients will be stratified into four groups according to the type of immunosuppressant therapy they receive: 1) cyclosporine, 2) sirolimus, 3) tacrolimus or 4) prednisolone+/-azathioprine, mycophenolate mofetil or mycophenolate sodium. Primary outcome measures will be changes in 1) arterial stiffness measured by aortic pulse wave velocity (PWV), 2) oxidative stress assessed by plasma isoprostanes and 3) inflammation by plasma pentraxin 3. Secondary outcomes will include changes in vascular function assessed using the brachial artery reactivity (BAR) technique, carotid artery intimal medial thickness (CIMT), augmentation index (AIx), left ventricular afterload and additional measures of oxidative stress and inflammation. Patients will undergo these measures at baseline, six and 12 months. Discussion The results of this study will help determine the efficacy of astaxanthin on vascular structure, oxidative stress and inflammation in renal transplant patients. This may lead to a larger intervention trial assessing cardiovascular morbidity and mortality. Trial Registration: ACTRN12608000159358

Item Details

Item Type:Refereed Article
Keywords:renal transplant; antioxidant; vascular function
Research Division:Medical and Health Sciences
Research Group:Clinical Sciences
Research Field:Nephrology and Urology
Objective Division:Health
Objective Group:Clinical Health (Organs, Diseases and Abnormal Conditions)
Objective Field:Urogenital System and Disorders
UTAS Author:Robertson, IK (Dr Iain Robertson)
UTAS Author:Geraghty, DP (Professor Dominic Geraghty)
UTAS Author:Sharman, JE (Professor James Sharman)
ID Code:53703
Year Published:2008
Web of Science® Times Cited:16
Deposited By:Health Sciences A
Deposited On:2008-12-22
Last Modified:2011-07-27
Downloads:402 View Download Statistics

Repository Staff Only: item control page